Fortress Biotech FBIO

Fortress Biotech, Inc. is a biopharmaceutical company focused on acquiring and advancing assets to enhance long-term value for shareholders through product revenue, equity holdings, dividend, and royalty income streams. The company identifies and evaluates promising products and product candidates in collaboration with key opinion leaders and through partnerships with leading universities, research institutes, and pharmaceutical companies. Following the acquisition or licensing of intellectual property, Fortress leverages its business, scientific, regulatory, legal, and financial expertise to support subsidiaries and partner companies in achieving development and commercialization goals.

Fortress generates revenue through multiple streams, including product sales from its commercialized therapeutics, equity holdings in publicly traded partner companies, dividend income, and royalty payments from licensed products. The company also benefits from milestone payments and potential future payments tied to regulatory and commercial achievements of its subsidiaries and partners. Revenue is derived from a diversified portfolio of assets across various therapeutic areas, reducing reliance on any single product or program.

The company operates through the following segments:

• Journey Medical Corporation: This segment markets and sells FDA-approved dermatology products in the United States. Key branded products include Emrosi for rosacea, Qbrexza for primary axillary hyperhidrosis, Accutane for severe acne, Amzeeq and Zilxi for acne and rosacea, Exelderm for antifungal treatment, Targadox for acne adjunctive therapy, and Luxamend for wound care. These products are distributed through pharmaceutical wholesalers, retail pharmacies, and dermatology clinics.
• Mustang Bio, Inc.: This segment focuses on developing chimeric antigen receptor (CAR) T-cell therapies and related technologies for oncology and rare diseases. Its lead candidate, MB-101, targets IL13Rα2 for glioblastoma and is being evaluated in combination with oncolytic virus MB-108 (HSV-1) as MB-109. Mustang also develops MB-106 for B-cell malignancies and AJ201 for spinal and bulbar muscular atrophy, both of which have received orphan drug designation from the FDA.
• Avenue Therapeutics, Inc.: This segment is developing intravenous formulations of existing therapeutics for hospital use. Its lead candidate, IV tramadol, is a Schedule IV opioid in development for post-operative acute pain, having completed Phase 3 efficacy studies. Avenue also holds a license from Duke University to develop ATX-04 (clenbuterol) for lysosomal storage diseases, with an initial focus on Pompe disease as an adjunct to enzyme replacement therapy.
• Cyprium Therapeutics, Inc.: This segment develops treatments for rare genetic disorders, primarily Menkes disease. Its lead product, ZYCUBO (copper histidinate, also known as CUTX-101), received FDA approval in January 2026 for pediatric patients with Menkes disease. Cyprium also advances AAV-ATP7A gene therapy for Menkes disease and is eligible to receive milestones and royalties from its partnership with Sentynl for ZYCUBO commercialization.

Fortress operates in the highly competitive biopharmaceutical industry, where it faces competition from large pharmaceutical companies, biotechnology firms, academic institutions, and research organizations. Its competitive advantage lies in its model of identifying and acquiring innovative assets early, then advancing them through strategic partnerships and internal expertise. The company’s focus on rare diseases and niche therapeutic areas allows it to address unmet medical needs with less direct competition than broader markets.

Fortress serves patients and healthcare providers through its subsidiaries and partner companies, with products used in dermatology clinics, hospitals, and specialty treatment centers. Its dermatology products are distributed via retail and specialty pharmacies, while its pipeline candidates target patients in oncology, neurology, and infectious disease settings. Specific end-users include individuals suffering from rare genetic disorders, cancer, and infectious diseases, supported by healthcare systems and managed care providers.